Abstract: The present invention relates to chemical and biological warfare agent decontaminating compositions and methods for using the same to decontaminate animal skin and wounds thereon exposed to the agents. The compositions may comprise a peracid, a hydroperoxide, and a peroxyacid.

Abstract: A sensor (e.g., an optical sensor) that may be implanted within a living animal (e.g., a human) and may be used to measure an analyte (e.g., glucose or oxygen) in a medium (e.g., interstitial fluid, blood, or intraperitoneal fluid) within the animal. The sensor may include a sensor housing, an analyte indicator covering at least a portion of the sensor housing, and one or more compounds having metal chelating moieties that reduce degradation of the analyte indicator.

Abstract: Wound-care composition and method of use. The composition comprises: a substrate; potassium alum; and urea. The potassium alum makes up 10.27 wt. % of the composition within a tolerance of +/- 50%; and the urea makes up 0.12 wt. % of the composition within a tolerance of +/- 50%. The method comprises applying the composition to a wound on a non-human animal.

Abstract: An application of a hydrogel in the preparation of products for the treatment of bacterial infection is disclosed. Ferrous ion was used in the antibacterial activity test of Staphylococcus aureus and showed a strong bactericidal effect, which the survival rate of Staphylococcus aureus is less than 0.001%, as well as the survival rate of methicillin-resistant Staphylococcus aureus (MRSA) was less than 0.01%. Ferrous ion hydrogel was used for the treatment of keratitis and skin wound infection. Ferrous ion hydrogel for the treatment of keratitis and skin wound infection, which can significantly reduce the risk of pulmonary MRSA infection, prevented the dissimilation of MRSA to the lung, and alleviated systemic inflammation in the body in a timely and effective manner, revealing the therapeutic potential of ferrous compounds for treatment of Staphylococcus aureus infections, including MRSA.

Abstract: A method is presented for treating viral and fungal infections by applying a topical immunosensitizer to the skin of a person infected with a virus or fungus and in need of treatment for the viral or fungal infection. Methods of improving anti-viral and anti-fungal immunity are also presented, and methods of increasing PBMC interferon gamma expression in response to a viral or fungal immune stimulus.

Abstract: Described are effervescent dissolvable solid structures comprising effervescent agglomerated particles which enhance the consumer experience and can improve dissolution of the structure. Also described are processes for the Dissolvable Solid Structure comprising effervescent agglomerated particles. Also described are methods for making the effervescent agglomerated particle.

Abstract: The present application discloses a composition for the treatment of Painful Damaged Disc Syndrome (PDDS), disc bulge, protrusion and herniation, and a delivery method and recommended treatment protocol for delivering thereto to a subject with an effective dosage of the composition. The composition has anti-inflammatory, antioxidant and vasodilating and antispasmodic properties. The compound is being administered via intravenous drip over a specified period for pain relief.

Abstract: The present invention relates to a hair cosmetic composition, especially for washing and/or conditioning hair, comprising surfactants and an oil-in-water emulsion that comprises: a silicone mixture comprising a trialkylsilyl terminated dialkylpolysiloxane and an amino silicone; a mixture of emulsifiers comprising one or more nonionic emulsifier, wherein the mixture of emulsifiers has a HLB value from 10 to 16; and water. The invention also relates to a process for the cosmetic treatment of hair, preferably for washing and/or conditioning hair, using this composition.

Abstract: Provided herein are compositions and methods for increasing butyrate production in a subject. In particular, provided herein are compositions, probiotic compositions, and combinations thereof that promote butyrate production in a subject.

Abstract: A 2-benzo-[3,4-b]quinolino-[b,g]indeno[1?,2?:3,4]fluoreno-[1,2-d]oxonine-24-chloro-5,11,16,21-tetraone compound, its synthesis, and its use as an antimicrobial agent.

Abstract: The disclosure relates to an extended-range spray applicator, and methods of making and use thereof, for dosing vaccines and/or probiotics to avian animals at a distance.

Abstract: An aqueous polymer dispersion with an average particle size of less than 1000 nm comprising a) a polymer carrier prepared by heterophase radical polymerization of at least one ethylenically unsaturated monomer in the presence of b) an oil-soluble organic UV absorber selected from the class of p-aminobenzoic acid derivatives; salicylic acid derivatives; benzophenone derivatives; diphenyl acrylate derivatives; benzofuran derivatives; polymeric UV absorbers, comprising one or more organosilicon radicals; cinnamic acid derivatives; camphor derivatives; s-triazine derivatives; trianilino-striazine derivatives; menthyl anthranilates; and benzotriazole derivatives; wherein the weight ratio of the oil-soluble organic UV absorber (b) to polymer carrier (a) is greater than 50 parts UV absorber per 100 parts of carrier; and c) a surfactant selected from c1) a nonionic surfactant selected from c11) the condensation product of a C6 to C18 fatty alcohol or C6 to C18 fatty acid and a mono- or disaccharide; and c2) an anioni

Abstract: Disclosed are stable extended release formulations and pharmaceutical compositions of Clozapine that exhibit improved stability under a variety of conditions, as well as processes for the preparation of such formulations and compositions.

Abstract: The present invention relates to an in-vivo bulking agent which can be used as a medicinal agent for prevention or treatment of at least one disease selected from the group consisting of urinary incontinence, fecal incontinence, and gastroesophageal reflux or as a filler for use in a plastic surgery procedure, and to a preparation method therefor. The in-vivo bulking agent can exhibit a bulking effect when injected into the body and particularly, is highly biocompatible because a first composition in which silicone particles are coated with a zwitterionic polymer having a surfactant property is introduced into a second composition, whereby the bulking agent can inhibit inflammatory reactions in vivo.

Abstract: There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stimulant; and (c) a second layer coated over the first layer, the second layer being present in an amount sufficient to substantially delay release of the active pharmaceutical ingredient in the first layer until after the coated bead reaches a distal intestine portion of a subject to whom the coated bead is administered; and (d) the third layer coated over the second layer, the third layer comprising a second amount of the active pharmaceutical ingredient, the third layer being configured to permit substantially immediate release of the active pharmaceutical ingredient comprised therein. Embodiments related to a solid oral pharmaceutical composition are also described.

Abstract: The present invention relates to sustained release tablet comprising micronized tolcapone, a release retardant and a binder, to said tablet for use in the prevention and/or treatment of a transthyretin-associated amyloidosis, to a method for the prevention and/or treatment of a transthyretin-associated amyloidosis comprising administering to a subject in need thereof an effective amount of said tablet, to pharmaceutical composition in the form of said tablet which is used in the prevention and/or treatment of a transthyretin-associated amyloidosis and to a process for the manufacture of said tablet.

Abstract: The present disclosure relates to bioactive hydrogels derived from human blood plasma. More particularly, the disclosure relates to multifunctional materials for cell encapsulation, cell culture platforms, medical treatment apparatus and methods, more particularly, hydrogels derived from human blood components and technologies for use of such materials in research, biomedical treatment, biotech and pharmaceutical industry. The disclosure further relates to 3D printable scaffolds, sponges, foams, fibers, particles, capsules, membranes and injectable systems comprising said hydrogel. Additionally, this disclosure allows for the controlled placement of biologically active components that may be delivered by the hydrogel compositions.

Abstract: A polyacrylonitrile (PANi) based pharmaceutical composition providing a porous implant for use in treating spinal cord trauma and/or spinal cord injury. Particularly a pharmaceutical composition including polyacrylonitrile (PANi) and/or elastin (E) and/or collagen (C) to form a PANi-E and/or PANi-C and/or a PANi-EC polymer network. Particularly, a pharmaceutical composition including polyacrylonitrile (PANi), elastin (E), and collagen (C) together forming a polyacrylonitrile (PANi), elastin (E), collagen (C) polymer network (PANi-E-C), wherein the polyacrylonitrile (PANi) may be crosslinked to form a crosslinked interpenetrating polyacrylonitrile (PANi), elastin (E) and collagen (C) polymer network (xpi-PANi-E-C), and wherein secondary protein structures of elastin (E) and collagen (C) reorientate. The disclosure extends to use of the pharmaceutical composition in the treatment of spinal cord trauma and/or spinal cord injury.

Abstract: Methods and compositions for treating disorders of the nail and nail bed. Such compositions contain a vehicle in which all components of the composition are dissolved, suspended, dispersed, or emulsified, a non-volatile solvent, a wetting agent, and a pharmaceutically active ingredient that is soluble in the non-volatile solvent and/or a mixture of the vehicle and the non-volatile solvent, and which composition is effective in treating a disorder of the nail or nail bed.

Abstract: Provided herein include caffeinated, partially decaffeinated, and decaffeinated paraxanthine beverages, coffees and paraxanthine coffee beverages. Also provided are methods for the production of caffeinated, partially decaffeinated, and decaffeinated paraxanthine beverages, coffees and paraxanthine coffee beverages. In some embodiments, disclosed compositions may provide consumers with increased alertness and wakefulness, while preventing side effects commonly associated with caffeinated drinks.